An appraisal of meta-analysis guidelines: how do they relate to safety outcomes?

被引:8
作者
Bennetts, Meg [1 ]
Whalen, Ed [2 ]
Ahadieh, Sima [3 ]
Cappelleri, Joseph C. [4 ]
机构
[1] Pfizer Ltd, Global Pharmacometr, Sandwich, Kent, England
[2] Pfizer Inc, Stat, New York, NY USA
[3] Pfizer Inc, Global Pharmacometr, Groton, CT USA
[4] Pfizer Inc, Stat, Groton, CT USA
关键词
systematic review; network meta-analysis; safety data; meta-analysis; data quality; RANDOMIZED CONTROLLED-TRIALS; CARE DECISION-MAKING; ISPOR TASK-FORCE; DRUG SAFETY; CELECOXIB; EVENTS;
D O I
10.1002/jrsm.1219
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although well developed to assess efficacy questions, meta-analyses and, more generally, systematic reviews, have received less attention in application to safety-related questions. As a result, many open questions remain on how best to apply meta-analyses in the safety setting. This appraisal attempts to: (i) summarize the current guidelines for assessing individual studies, systematic reviews, and network meta-analyses; (ii) describe several publications on safety meta-analytic approaches; and (iii) present some of the questions and issues that arise with safety data. A number of gaps in the current quality guidelines are identified along with issues to consider when performing a safety meta-analysis. While some work is ongoing to provide guidance to improve the quality of safety meta-analyses, this review emphasizes the critical need for better reporting and increased transparency regarding safety data in the systematic review guidelines. Copyright (C) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:64 / 78
页数:15
相关论文
共 43 条
[1]   Evidence Synthesis for Decision Making 7: A Reviewer's Checklist [J].
Ades, A. E. ;
Caldwell, Deborah M. ;
Reken, Stefanie ;
Welton, Nicky J. ;
Sutton, Alex J. ;
Dias, Sofia .
MEDICAL DECISION MAKING, 2013, 33 (05) :679-691
[2]   Safety of Immunosuppressive Drugs Used as Maintenance Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis [J].
Almeida, Celline Cardoso ;
Silveira, Micheline Rosa ;
de Araujo, Vania Eloisa ;
Pires de Lemos, Livia Lovato ;
Costa, Juliana de Oliveira ;
Lins Reis, Carlos Augusto ;
Acurcio, Francisco de Assis ;
Braga Ceccato, Maria das Gracas .
PHARMACEUTICALS, 2013, 6 (10) :1170-1194
[3]   Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data [J].
Askling, Johan ;
Fahrbach, Kyle ;
Nordstrom, Beth ;
Ross, Susan ;
Schmid, Christopher H. ;
Symmons, Deborah .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (02) :119-130
[4]  
Baker WL, 2016, UMBRELLA REV EVIDENC, P115
[5]   GRADE guidelines: 3. Rating the quality of evidence [J].
Balshem, Howard ;
Helfand, Mark ;
Schuenemann, Holger J. ;
Oxman, Andrew D. ;
Kunz, Regina ;
Brozek, Jan ;
Vist, Gunn E. ;
Falck-Ytter, Yngve ;
Meerpohl, Joerg ;
Norris, Susan ;
Guyatt, Gordon H. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :401-406
[6]  
Barkhuizen A, 2006, J RHEUMATOL, V33, P1805
[7]   Meta-analysis of clinical trial safety data in a drug development program: Answers to frequently asked questions [J].
Berlin, Jesse A. ;
Crowe, Brenda J. ;
Whalen, Edward ;
Xia, H. Amy ;
Koro, Carol E. ;
Kuebler, Juergen .
CLINICAL TRIALS, 2013, 10 (01) :20-31
[8]  
Biando- Zoccai G, 2014, NETWORK METAANALYSIS
[9]  
Borenstein M., 2009, INTRO META ANAL
[10]   Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events [J].
Bradburn, Michael J. ;
Deeks, Jonathan J. ;
Berlin, Jesse A. ;
Localio, A. Russell .
STATISTICS IN MEDICINE, 2007, 26 (01) :53-77